|Bid||0.00 x 800|
|Ask||239.83 x 1000|
|Day's Range||233.23 - 236.21|
|52 Week Range||139.64 - 241.82|
|Beta (3Y Monthly)||0.82|
|PE Ratio (TTM)||64.44|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Edwards Lifesciences (EW) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Wedgewood Partners, a St. Louis, Missouri-based investment firm, has released its 2019 Q3 investor letter – you can download a copy here. The investment firm reported mixed results for the quarter, with composite returns largely flat at 0.39% for the quarter. Meanwhile, the benchmark Russell 1000 Growth Index and the S&P 500 Index gained 1.49% and 1.87%, respectively. Wedgewood Partners wrote extensively […]
Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
DexCom's (DXCM) Q3 earnings benefit from higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook. However, contraction in gross margin remains a woe.
Albeit Option Care Health (BIOS) is yet to reap material benefits from its merger-related synergies, the reporting of a positive gross margin in third-quarter results is encouraging for investors.
Cardinal Health (CAH) Q1 results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.
Insulet's (PODD) year-over-year improvement in Q3 revenues on the solid uptake of Omnipod system both in the United States and across international markets looks promising.
Allscripts (MDRX) third-quarter results gain from growth in bookings and solid segmental performance. Contraction in both gross and operating margins remains a woe.
Luminex's (LMNX) Q3 earnings benefit from higher revenues and solid performance across System Sales, Consumable Sales and Service Revenues. However, gross margin contraction remains a woe.